Stryker remains a buy despite Q1 hit from cyberattack, with strong dividend growth and undervalued stock price.

Stryker, a medical technology leader and Dividend Aristocrat with 32 years of dividend increases, faced a cybersecurity incident impacting its Q1 2026 results. Despite this, management upheld its full-year guidance and expects business normalization soon. The stock trades at about 21 times estimated 2026 earnings per share, below its five-year average, indicating potential undervaluation. The company's robust cash flow, conservative dividend payout, and diversified growth strategy through acquisitions support a 'buy' rating.